

October 28, 2023

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Launch of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a generic version of Abraxane®

Reg.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Panacea Biotec Limited, one of India's leading biotechnology company, is pleased to announce the launch of **Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)**, a generic version of Abraxane® in the Canadian market by its material wholly-owned subsidiary company viz. Panacea Biotec Pharma Limited through its strategic partner Apotex Inc., Canada.

Paclitaxel Protein-Bound Particles for Injectable Suspension is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas. ABRAXANE® is a registered trademark of Abraxis BioScience, LLC, which is a wholly owned subsidiary of Bristol- Myers Squibb Company.

This is the first generic launch of Abraxane® in Canada and provides patients with a high quality medication at an affordable price. The current market size of Abraxane® in Canada is US\$26.4 million (using a CAD\$1.39:US\$1 exchange rate) (Source: IQVIA CDH Moving Annual Total (MAT) September 2023).

Panacea Biotec had an existing collaboration agreement with Apotex Inc. for research, development, license, supply and sale of the said Product in US, Canada, Australia & New Zealand. Pursuant to the said collaboration agreement Panacea Biotec had undertaken research, development and manufacturing of the product at its state-of-the-art pharmaceutical formulations facility at Baddi, Himachal Pradesh and Apotex Inc. will undertake the marketing, sales and distribution thereof in the Canadian market.

The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, SEBI master Circular SEBI/HO/CFD/PoD2/ CIR/P/2023/120 dated July 11, 2023 and SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is annexed as **Annexure – A**.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

Vinod Goel

Group CFO and Head Legal & Company Secretary

Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9015 Email: corporate@panaceabiotec.com

Annexure - A

1.	Name of the Product	Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a generic version of Abraxane®
2.	Date of Launch	October 27, 2023
3.	Category of the Product	Pharmaceutical
4.	Whether caters to domestic / international market	International market
5.	Name of the countries in which the product is launched (in case of international)	Canada